insights_auto
Kāpēc uzņēmuma GIS akciju cena ir pieaugusi 3,38%?
Atklājiet vairāk iespējuchevron_right
GIS:FRA
Gilead Sciences, Inc
135,30 €
arrow_upward
+3,38%(+4,42) 1 d.
12. okt., 13:57:29 GMT+2 · EUR
search
Visi simboli
| Simbols | Cena | Izmaiņas | % izmaiņu |
|---|
insights_autoNotiek galveno ieskatu ģenerēšana par šādu tēmu: GIS…
Atvērt
134,80 €
Augsta
135,30 €
Zema
134,80 €
Tirgus kapitalizācija
188,39 mljrd.
Vid. apjoms
386,00
Apjoms
53,00
Augstākā 52 ned.
135,30 €
Zemākā 52 ned.
97,79 €
Darbinieku skaits
17 tūkst.
Atvērt
134,80 €
Augsta
135,30 €
Zema
134,80 €
Tirgus kapitalizācija
188,39 mljrd.
Vid. apjoms
386,00
Apjoms
53,00
Augstākā 52 ned.
135,30 €
Zemākā 52 ned.
97,79 €
Darbinieku skaits
17 tūkst.
Ziņas un raksti
No tīmekļa avotiem un ziņu partneriem
Investing.com
·
pirms 2 stundām
BofA raises Gilead Sciences stock price target on growth outlook
ad-hoc-news.de
·
pirms 3 stundām
RBC raised target for Gilead Sciences stock to USD 126.00
ad-hoc-news.de
·
pirms 7 stundām
Gilead Sciences stock pre-market at EUR 135.08: plus 1.08 percent versus the Xetra close
Yahoo Finance
·
pirms 2 dienām
Why Is Everyone Ignoring Gilead Stock's High Cash Yield?
Profils
Gilead Sciences, Inc. is an American biopharmaceutical company headquartered in Foster City, California, that focuses on researching and developing antiviral drugs used in the treatment of HIV/AIDS, hepatitis B, hepatitis C, influenza, and COVID-19. It also develops medicines in therapeutic areas such as oncology and inflammation and cell therapy.
In 1987, Michael L. Riordan founded the company under the name Oligogen. The original name was a reference to oligonucleotides, small strands of DNA used to target genetic sequences. Gilead held its initial public offering in 1992, and successfully developed drugs including Tamiflu and Vistide that decade.
In the 2000s, Gilead began evolving from a biotechnology company into a large pharmaceutical company, through acquisitions and investments, acquiring several subsidiaries. Gilead is a member of the Nasdaq-100 and the S&P 100.
The company has faced criticism over its business practices, including extremely high pricing of drugs such as Sovaldi and Truvada in the United States relative to production cost and cost in the developing world. Wikipedia
Par “Gilead Sciences, Inc”
ĢenerāldirektorsDaniel O'Day
Darbinieki17 tūkst.
Dibināšanas datums1987. gada 22. jūn.
Galvenais birojsFoster City, Kalifornija, Amerikas Savienotās Valstis
Sektors-
Tīmekļa vietnegilead.com